< Back to previous page
Researcher
Xavier Saelens
- Keywords (Ghent University):antiviral immunity, virology, vaccines
- Disciplines (Flanders Institute for Biotechnology):Analytical biochemistry, Cell death and senescence, Analysis of next-generation sequence data, General diagnostics
- Disciplines (Ghent University):Applied immunology, Drug discovery and development not elsewhere classified, Clinical trials, Biopharmaceuticals, In vitro testing, Non-clinical studies, Animal immunology, Transcription and translation, Vaccines, Molecular and cell biology not elsewhere classified, Virology
Affiliations
- Department of Biochemistry and microbiology (Department)
Member
From1 Oct 2018 → Today - Saelens Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Biomedical molecular biology (Department)
Member
From1 Jan 1996 → 30 Sep 2018 - Department of Plant Biotechnology and Bioinformatics (Department)
Member
From1 Jan 1993 → 31 Dec 1995
Projects
1 - 10 of 49
See also Xavier Saelens for projects of Flanders Institute for Biotechnology.
Here below the projects of Ghent University.
- Blocking virus entry using structure-guided designed biologics.From1 Nov 2024 → TodayFunding: FWO Strategic Basic Research Grant
- FullPicture: Combining Spectral Flow Cytometry with High-Speed Cell Imaging to enable comprehensive profiling of plant and animal cells and their components in real time.From1 May 2024 → TodayFunding: FWO Medium Size Research Infrastructure
- Virus ResearchFrom1 Jan 2024 → TodayFunding: BOF - projects
- Development of intrabody-expressing influenza virus vectors to discover new pro- and antiviral host factorsFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- New antivirals against human parainfluenza virusFrom1 Apr 2023 → 30 Sep 2024Funding: IOF - technology validation in lab
- Flow imaging microscope for advanced analysis of biopharmaceuticals and biological samplesFrom15 Dec 2022 → 14 Dec 2024Funding: BOF - scientific equipment program
- Prepared for SARS-CoV-3: advancing our understanding of SARS coronavirus antigenic and pathogenic evolutionFrom1 Jan 2022 → TodayFunding: FWO EOS
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseases.From1 Nov 2021 → 15 Nov 2025Funding: FWO Strategic Basic Research Grant
- A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseasesFrom1 Oct 2021 → 31 Oct 2021Funding: BOF - doctoral mandates
- A nanobody-based anti-inflammatory treatment against pathogen-induced chronic lung inflammationFrom1 Oct 2021 → 30 Sep 2025Funding: BOF - projects
Publications
1 - 10 of 175
See also Xavier Saelens for publications of Flanders Institute for Biotechnology.
Here below the publications of Ghent University.
- Unraveling the immunosuppressive role of Elastase B produced by cystic fibrosis isolates of Pseudomonas aeruginosa in an organotypic 3D lung epithelial cell model(2025)Published in: VIRULENCEISSN: 2150-5608Issue: 1Volume: 16
- Myxovirus resistance (Mx) interacting proteins(2025)Pages: XIV, 300 p.
- Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses(2025)Published in: NATURE COMMUNICATIONSISSN: 2041-1723Issue: 1Volume: 16
- Pan-influenza B control with single-domain antibodies directed against hemagglutinin and neuraminidase(2025)Pages: XX, 274 p.
- MX2 forms nucleoporin-comprising cytoplasmic biomolecular condensates that lure viral capsids(2024)Published in: CELL HOST & MICROBEISSN: 1934-6069Issue: 10Volume: 32Pages: 1705 - 1724.e14
- Direct and ultrasensitive bioluminescent detection of intact respiratory viruses(2024)Published in: ACS SENSORSISSN: 2379-3694Issue: 10Volume: 9Pages: 5550 - 5560
- The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017(2024)Published in: ELIFEISSN: 2050-084XVolume: 12
- Systematic review and meta-analysis of genome-wide pooled CRISPR screens to identify host factors involved in influenza A virus infection(2024)Published in: JOURNAL OF VIROLOGYISSN: 1098-5514Issue: 5Volume: 98
- Promises and challenges of single-domain antibodies to control influenza(2024)Published in: ANTIVIRAL RESEARCHISSN: 1872-9096Volume: 222
- Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa(2024)Published in: SCIENCE TRANSLATIONAL MEDICINEISSN: 1946-6242Issue: 770Volume: 16
Patents
1 - 10 of 10
- ANTIVIRALS AGAINST HUMAN PARAINFLUENZA VIRUS
- SARBECOVIRUS SPIKE S2 SUBUNIT BINDERS
- PAN-SPECIFIC CORONA VIRUS BINDERS
- SARBECOVIRUS BINDERS
- ANTIBODY COMPOSITIONS FOR TREATMENT OF CORONA VIRUS INFECTION
- SINGLE DOMAIN ANTIBODY AGAINST RSV F PROTEIN
- CORONA VIRUS BINDERS
- METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE
- MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL
- Anti-influenza antibody